Showing items 1 - 20 of 36

Your selections:

Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial

Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention

Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia

Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study

Health and Social Characteristics of Clients Reporting Amphetamine Type Substance Use at Entry to Public Alcohol and Other Drug Services in New South Wales, Australia, 2016–2019

Assessing the concurrent validity, inter-rater reliability and test-re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations

Assessing the validity of the Australian treatment outcomes profile for telephone administration in drug health treatment populations

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder

An evaluation of the prescription of opioids for chronic nonmalignant pain by Australian general practitioners

An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy

Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal

Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: the Opioid-Related Behaviours In Treatment (ORBIT) scale

Nabiximols for the treatment of cannabis dependence: a randomized clinical trial

  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit